Investment Thesis
Mangoceuticals faces imminent going concern risk with revenue collapsed 26% YoY to $67.9K while burning $1.3M quarterly in operations, leaving only $174.6K cash (6-8 weeks runway). The company is destroying shareholder value with -5014.7% net margin and -23.6% ROA, indicating fundamental operational failure at current scale.
Strengths
- Reasonable gross margin of 42.7% suggests viable unit economics if revenue could scale
- Minimal debt burden (0.00x debt/equity) prevents leverage amplification of distress
- Positive shareholders' equity of $13.5M provides limited balance sheet buffer
Risks
- Critical liquidity crisis: current ratio of 0.29x with $174.6K cash against $1.3M quarterly burn rate indicates 6-8 weeks operational runway without capital injection
- Revenue collapse of 26% YoY to $67.9K magnitude signals fundamental business model failure or market rejection
- Severe unprofitability with -5014.7% net margin and -23.6% ROA demonstrates complete operational inefficiency at current revenue scale
Key Metrics to Watch
- Cash balance and monthly burn rate (going concern threshold)
- Revenue stabilization and month-over-month growth trajectory
- Capital injection announcement or operating cash flow path to breakeven
Financial Metrics
Revenue
67.9K
Net Income
-3.4M
EPS (Diluted)
$-0.22
Free Cash Flow
-1.3M
Total Assets
14.4M
Cash
174.6K
Profitability Ratios
Gross Margin
42.7%
Operating Margin
-4,606.8%
Net Margin
-5,014.7%
ROE
-25.3%
ROA
-23.6%
FCF Margin
-1,937.5%
Balance Sheet & Liquidity
Current Ratio
0.29x
Quick Ratio
0.27x
Debt/Equity
0.00x
Debt/Assets
6.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:44:07.394053 |
Data as of: 2026-03-31 |
Powered by Claude AI